The beneficial effect of high dose chemotherapy with HSCT in patients with advanced ovarian carcinoma, with complete clinical remission

Andrzej Lange; Joanna Werkun; Dorota Dłubek; Cezary Juda; Marian Gryboś; Ilona Kryczek

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2006
vol. 10

Send email

Copy url:

abstract:

The beneficial effect of high dose chemotherapy with HSCT in patients with advanced ovarian carcinoma, with complete clinical remission

Andrzej Lange

,

Joanna Werkun

,

Dorota Dłubek

,

Cezary Juda

,

Marian Gryboś

,

Ilona Kryczek

Współcz Onkol 2006; 5: 236-239

Online publish date: 2006/06/26

View full text Get citation

Twenty-two patients with advanced ovarian carcinoma underwent
high-dose chemotherapy supported by hematopoietic stem cell transplantation.
Ten patients received double transplantation following ICE and CME,
respectively. Twelve patients received only one course of high dose chemotherapy
(CME, ICE, Melphalan and Carboplatine or Melphalan). Seven and 15 patients
were in CR and PR prior to autologous HSCT, respectively. Toxicity was in a
majority of cases manageable. One patient died due to infection complication
after the second transplant. All patients were followed and their fate registered.
It was shown that patients in clinical remission prior to HD chemotherapy
enjoyed statistically significant better two years survival as compared to those with
PR (83% vs 37%, p=0.049). The median follow-up of patients was 24.7 months
in the CR group and 12.5 months in PR group. Overall cumulative proportion of survival was significantly better in the group with CR prior to the procedure.
There was no difference in overall survival with respect to one or two HD
chemotherapy courses and to length of the disease. The survival of patients with
PR was unsatisfactory calling for a maintenance involving immunotherapy
according to the recent progress in this field.

keywords:

The beneficial effect of high dose chemotherapy with HSCT in patients with advanced ovarian carcinoma, with complete clinical remission

Andrzej Lange , Joanna Werkun , Dorota Dłubek , Cezary Juda , Marian Gryboś , Ilona Kryczek

ovarian carcinoma, HSCT, cumulative proportion of survival

Andrzej Lange

,

Joanna Werkun

,

Dorota Dłubek

,

Cezary Juda

,

Marian Gryboś

,

Ilona Kryczek